Current and evolving features in the clinical management of haemophilia

Blood Transfusion

Volumn 12, Issue SUPPL. 3, 2014, Pages

  Coppola, Antonio ^a   Morfini, Massimo ^b   Cimino, Ernesto ^a   Tufano, Antonella ^a   Cerbone, Anna M ^a   Di Minno, Giovanni ^a  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^b Italian Association of Haemophilia Centres (AICE)   (Italy)

Author keywords

Bleeding; Comprehensive care; Haemophilia; Prophylaxis; Treatment.

Indexed keywords

AGING; HEALTH CARE DELIVERY; HEMOPHILIA; PATIENT CARE; PROPHYLAXIS; REVIEW; HEMOPHILIA A; HUMAN; PROCEDURES; STANDARDS;

AGING; DELIVERY OF HEALTH CARE; HEMOPHILIA A; HUMANS;

EID: 84901594073     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2014.0043-14s     Document Type: Review

References (86)

1. Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 2012; 7:24.
2. Tagliaferri A, Rivolta GF, Iorio A, et al. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010; 16: 437-46.
3. Franchini M, Coppola A, Molinari AC, et al. Forum on: the role of recombinant factor VIII in children with severe haemophilia A. Haemophilia 2009; 15: 578-86.
4. Ofosu FA, Freedman J, Semple JW. Plasma-derived biological medicines used to promote haemostasis. Thromb Haemost 2008; 99: 851-62. (Pubitemid 351705301)
5. Franchini M, Lippi G. Recombinant factor VIII concentrates. Semin Thromb Hemost 2010; 36: 493-7.
6. Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost 2012; 38: 79-94.
7. Coppola A, Franchini M, Tagliaferri A. Prophylaxis in people with hemophilia. Thromb Haemost 2009; 101: 674-81.
8. Gringeri A, Lambert T, Street A, Aledort L. Adolescent/Adult Prophylaxis Expert Working Group of the International Prophylaxis Study Group. Tertiary prophylaxis in adults: is there a rationale? Haemophilia 2012; 18: 722-8.
9. Colvin BT, Astermark J, Fischer K, et al. European principles of haemophilia care. Haemophilia 2008, 14: 361-74. (Pubitemid 351338698)
10. Coppola A, Santoro C, Franchini M, et al. Emerging issues on comprehensive hemophilia care: preventing, identifying and monitoring age-related comorbidities. Semin Thromb Hemost 2013; 39: 794-802.
11. Donadel-Claeyssens S. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia 2006; 12: 124-7.
12. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis vs episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44. (Pubitemid 47236278)
13. Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007; 13 (Suppl 5): 65-8. (Pubitemid 350253407)
14. Hay CR, DiMichele DM; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
15. Manco-Johnson MJ, Kempton CL, Reding MT, et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs on-demand treatment with rFVIII-FS in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11: 1119-27.
16. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of haemophilia. HaemophiliaHaemophilia 2013; 19: e1-47.
17. Forsyth AL, Giangrande P, Hay CRM et al. Difficult clinical challenges in haemophilia: international experiential perspective. Haemophilia 2012; 18(Suppl. 5): 39-45.
18. Peyvandi F, Garagiola I, Seregni S. Future of factor replacement treatment. J Thromb Haeamost 2013; 11: 84-98.
19. Chuah MK, Nair N, van den Driessche T. Recent progress in gene therapy for hemophilia. Hum Gene Ther 2012; 23: 557-65.
20. Gringeri A, Lundin B, Mackensen SV, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
21. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H: Twenty-five years experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
22. Fischer K, van der Bom JG, Mauser-Bunschoten EP, et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99: 2337-41. (Pubitemid 34525418)
23. Aledort L, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9. (Pubitemid 24323199)
24. Berntorp E, Boulyjenkov V, Brettler D, et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73: 691-701. (Pubitemid 26020631)
25. Richards M, Williams M, Chalmers E, et al. Paediatric Working Party of the United Kingdom Haemophilia Doctors' Organisation. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology. Guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol 2010; 149: 498-507.
26. Santoro C, Baldacci E, Mercanti C, Mazzucconi MG. Tailored vs. standard dose prophylaxis in children with haemophilia A. Semin Thromb Hemost 2013; 39: 711-22.
27. Feldman BM, Pai M, Rivard GE, et al. Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-36.
28. Valentino LA, Mamonov V, Hellmann A, et al. Prophylaxis Study Group: Prophylaxis Study Group. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359-67.
29. Wu R, Luke KH, Poon MC, et al. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. Haemophilia 2011, 17:70-4.
30. Celkan T, Özdemir N. Reduced early prophylaxis of children with haemophilia in a developing country, Turkey. Haemophilia 2011; 17: e840-e841.
31. Tagliaferri A, Franchini M, Coppola A, et al. Effects of secondary prophylaxis started in young-adult hemophiliacs. Haemophilia 2008; 14: 945-51.
32. Collins P, Faradji A, Morfini M, et al. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010; 8: 83-9.
33. Tagliaferri A, Rivolta GF, Coppola A, et al. Prophylaxis vs on-demand therapy through economic report (POTTER) study: Preliminary data from the final five-year analysis. Haemophilia 2012; 18 (Suppl. 3):160 (abstract).
34. National Hemophilia Foundation. MASAC Recommendations concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Document 179. Available at: http://www.hemophilia.org/NHFWeb/MainPgs/ MainNHF.aspx?menuid=57&contentid=1007. Accessed on 13/02/2014.
35. van Dijk K, Fischer K, van der Bom JG, et al. Can long term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005; 130: 107-12. (Pubitemid 40979141)
36. Noon D, O'Mahony B, van Dijv JP, Prihodova L. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries. Haemophilia 2013; 19: 44-50.
37. Farrugia A, Cassar J, Kimber MC, et al. Treatment for life for severe haemophilia A - A cost-utility model for prophylaxis vs. on-demand treatment. Haemophilia 2013; 19: e228-38.
38. Soucie JM, Nuss R, Evatt B, et al. Mortality among males with hemophilia: relations with source of medical care. Blood 2000; 96: 437-42. (Pubitemid 30463360)
39. Baker JR, Crudder So, Riske B, et al. A model for a regional system of care to promote the health and well-being of people with rare chronic genetic disorders. Am J Public Health 2005; 95: 1910-6.
40. Fischer K, Hermans C, on behalf of the European Haemophilia Therapy Standardisation Board (EHTSB). The European Principles of Haemophilia Care: a pilot investigation of adherence to the principles in Europe. Haemophilia 2013; 19: 35-43.
41. Mauser-Bunschoten EP, van de Putte DEF, Schutgens REG. Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. Haemophilia 2009; 15: 853-63.
42. Mannucci PM, Schutgens RE, Santagostino E, Mauser-Bunschoten EP. How I treat age-related morbidities in elderly persons with hemophilia. Blood 2009; 114: 5256-63.
43. Coppola A, Tagliaferri A, Franchini M. The management of cardiovascular diseases in patients with hemophilia. Semin Thromb Hemost 2010; 36: 91-102.
44. Tagliaferri A, Di Perna C, Santoro C, et al. Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centres. J Thromb Haemost 2012; 10: 90-5.
45. Lambing A, Kachalsky E, Kuriakose P. Liver transplantation in the haemophilia patient. Haemophilia 2012; 18: 300-3.
46. Hay CR, Palmer B, Chalmers E, et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367-70.
47. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM: Central venous devices in haemophilia. Haemophilia 2004, 10:134-46.
48. Ljung R. The risk associated with indwelling catheters in children with haemophilia. Br J Haematol 2007; 138: 580-6. (Pubitemid 47206720)
49. Mancuso M, Berardinelli L, Beretta C, et al. Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up. Haematologica 2009; 94: 687-92.
50. Bui S, Babre F, Hauchecorne S, et al. Intravenous peripherally-inserted central catheters for antibiotic therapy in children with cystic fibrosis. J Cyst Fibros 2009; 8: 326-31.
51. Franchini M, Mannucci PM. Inhibithors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol 2011; 72: 553-62.
52. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63. (Pubitemid 37193570)
53. Coppola A, Santoro C, Franchini M, Tagliaferri A, Di Minno G. Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies. Haemophilia 2010; 16: 13-9.
54. Astermark J. Inhibitor development: patient-determined risk factors. Haemophilia 2010; 16: 66-70.
55. Astermark J, Donfield SM, Gomperts ED, et al. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood 2013; 121: 1446-54.
56. Matzinger P. The danger model: a renewed sense of self. Science 2002; 8: 76-82.
57. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54. (Pubitemid 46827754)
58. Maclean PS, Richards M, Williams M, Collins P, Liesner R, Keeling DM, Yee T, Will AM, Young D, Chalmers EA. Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia 2011; 17: 282-7.
59. Gouw SC, van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013; 121: 4046-55.
60. Santagostino E, Mancuso ME, Rocino A, et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422-7. (Pubitemid 43899592)
61. Auerswald G, Bidlingmaier C, Kurnik K. Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients-long-term follow-up and continuing experience. Haemophilia 2012; 18: e18-e20.
62. Goudemand J, Rothschild C, Demiguel V, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51. (Pubitemid 43054971)
63. Mancuso ME, Mannucci PM, Rocino A, et al. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A. J Thromb Haemost 2012; 10: 781-90.
64. Gouw SC, van der Bom JG, Ljung R, et al; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231-9.
65. Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously-untreated hemophilia a patients treated with plasma-derived or recombinant factor VIII concentrates. A systematic review. J Thromb Haemost 2010; 8: 1256-65.
66. Franchini M, Coppola A, Rocino A, et al. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia A: a 2013 update. Semin Thromb Hemost 2013; 39: 752-66.
67. Ter Avest P, Fischer K, Mancuso ME, et al. Risk stratification for inhibitor development at first treatment for severe haemophilia A patients: a tool for clinical practice. J Thromb Haemost 2008; 6: 2048-54.
68. Auerswald G, Bidlingmaier C, Kurnik K. Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients - long-term follow-up and continuing experience. Haemophilia 2012; 18: e18-e20.
69. Astermark J, Morado M, Rocino A, et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006;12:363-71.
70. DiMichele D, Hoots WK, Pipe SW, et al. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13: 1-22 (Pubitemid 47009242)
71. Coppola A, Di Minno MN, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 2010; 150: 515-28.
72. Collins PW, Chalmers E, Hart DP, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol 2013; 160: 153-170.
73. Hay CR, DiMichele DM; International Immune Tolerance Study: The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
74. Coppola A, Margaglione M, Santagostino E, et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 2009; 7: 1809-15.
75. Di Minno MND, Di Minno G, Di Capua M, et al. Cost of care of haemophilia with inhibitors. Haemophilia 2010, 16: e190-e201.
76. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13. (Pubitemid 47288949)
77. Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684-92.
78. Young G, Auerswald G, Jimenez-Yuste V, et al. PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. Thromb Res 2012; 130: 864-70.
79. Gringeri A, Leissinger C, Cortesi PA, et al. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study. Haemophilia 2013; 19: 736-43.
80. Franchini M, Coppola A, Rocino A, et al. Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters. The 2013 AICE survey. Haemophilia 2014; 20: e128-35.
81. Di Minno G, Canaro M, Ironside JW, et al. Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threats. Semin Thromb Hemost 2013; 39: 779-93.
82. Tarantino MD, Ye X, Bergstrom F, Skorija K, Luo MP. The impact of the economic downturn and health care reform on treatment decisions for haemophilia A: patient, caregiver and health care provider perspectives. Haemophilia 2013; 19: 51-8.
83. Kaufman RJ, Powell JS. Molecular approaches for improved clotting factors for hemophilia. Blood 2013; 122: 3568-74.
84. Hart DP. Prophylaxis in the era of long-acting products. Haemophilia 2014; 20(Suppl 2): 7 SP008 (abstract).
85. DiMichele DM. Inhibitors in haemophilia B: An orphan disease in need of attention. Br J Haematol 2007; 138: 305-15.
86. Santagostino E, Fasulo MR. Hemophilia A and hemophilia B: different types of diseases? Semin Thromb Hemost 2013; 39: 697-701.